| Description | ALX-1393 is a selective GlyT2 inhibitor that effectively reduces neuronal action potential activity in a concentration-dependent manner and inhibits the activity of spontaneous networks by inducing glycinergic tetanic currents in the abdominal horn of the spinal cord. Antiinjurious effects on thermal, mechanical and chemical stimuli in rat models of acute pain. |
| In vivo | ALX1393 (i.c.v.; 25, 50, 和 100 μg) 在正常大鼠的福尔马林试验中抑制晚期反应，而对运动性能无影响。此外，ALX1393 表现出对机械和冷痛觉过敏的剂量依赖性抑制作用。[1] |
| molecular weight | 395.42 |
| Molecular formula | C23H22FNO4 |
| CAS | 949164-09-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 11 mg/mL (27.82 mM) |
| References | 1. Takahashi Y, et al. Antinociceptive effect of intracerebroventricular administration of glycine transporter-2 inhibitor ALX1393 in rat models of inflammatory and neuropathic pain. Pharmacol Biochem Behav. 2015;130:46-52. 2. Haranishi Y, et al. The antinociceptive effect of intrathecal administration of glycine transporter-2 inhibitor ALX1393 in a rat acute pain model. Anesth Analg. 2010;110(2):615-621. 3. Hermanns H, et al. Differential effects of spinally applied glycine transporter inhibitors on nociception in a rat model of neuropathic pain. Neurosci Lett. 2008;445(3):214-219. |